Amongst sufferers with high-risk, HER2-positive early breast most cancers, presurgical, or neoadjuvant, remedy with Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) adopted by paclitaxel, Herceptin (trastuzumab) and Perjeta (pertuzumab, THP) was related to an enchancment in pathologic full response (pCR) price in contrast with dose-dense doxorubicin and cyclophosphamide plus THP (ddAC-THP), knowledge from the section 3 DESTINY-Breast11 trial has proven.
Findings offered on the 2025 ESMO Congress demonstrated that sufferers handled with Enhertu adopted by THP (321 sufferers) skilled a pCR price of 67.3% in contrast with 56.3% for these given ddAC-THP (320 sufferers; distinction, 11.2%). Notably, the pCR profit was noticed within the hormone receptor–optimistic inhabitants, the place the pCR price was 61.4% within the Enhertu arm (236 sufferers) versus 52.3% within the ddAC-THP arm (235 sufferers; distinction, 9.1%), in addition to the hormone receptor–damaging inhabitants, the place the respective pCR charges for the Enhertu arm (83 sufferers) and ddAC-THP arm (85 sufferers) have been 83.1% and 67.1% (distinction, 16.1%).
Glossary
Glossary
Pathologic full response (pCR): which means when the medical doctors take a look at the eliminated tissue underneath a microscope, there aren’t any indicators of remaining invasive most cancers.
Occasion-free survival (EFS): that is the size of time an individual stays alive with out their most cancers coming again, getting worse, or creating a second most cancers.
Pharmacokinetics: that is what your physique does to a drug, which incorporates how the drug is absorbed, distributed, modified, and ultimately eliminated.
Invasive disease-free survival: that is the time an individual lives with out the return of the invasive most cancers or a second invasive most cancers, and with out loss of life from any trigger.
General survival: this refers back to the share of individuals in a research who’re nonetheless alive after a sure time period.
Residual most cancers burden (RCB): this can be a measure that estimates how a lot most cancers is left within the breast and lymph nodes after neoadjuvant remedy (remedy given earlier than surgical procedure).
ECOG efficiency standing: this can be a scale that medical doctors use to explain a affected person’s basic well-being and the way succesful they’re of performing strange every day duties.
Interstitial lung illness (ILD): this can be a group of lung problems that trigger scarring of the lungs, which might make it exhausting to breathe.
Left ventricular dysfunction: this can be a situation the place the primary pumping chamber of the guts (the left ventricle) isn’t working in addition to it ought to.
Elevated transaminase ranges: this can be a signal of liver harm or damage that’s detected by blood assessments measuring the degrees of sure liver enzymes.
Neutropenia: this can be a situation by which an individual has a low variety of neutrophils, that are a selected sort of white blood cell vital for combating an infection.
Peripheral neuropathy: this refers to nerve harm outdoors of the mind and spinal twine, which might trigger numbness, tingling, or ache, typically within the palms or toes.
Anemia: this can be a situation the place your physique doesn’t have sufficient wholesome pink blood cells to hold sufficient oxygen to your tissues, typically resulting in fatigue.
Stomatitis: this can be a basic time period for irritation or soreness contained in the mouth, which might embody mouth sores.
Leukopenia: this can be a situation the place an individual has a low general variety of white blood cells, which might put them at a better threat of an infection.
“DESTINY-Breast11 confirmed the best reported pCR price in HER2-positive early breast most cancers for a registrational research within the neoadjuvant setting, regardless of — if you wish to do cross-trial comparisons — a excessive prevalence of hormone receptor–optimistic illness and a high-risk inhabitants,” lead research creator Dr. Nadia Harbeck stated in a presentation of the information.
Harbeck is director of the Breast Heart and chair for Conservative Oncology on the Division of OB&GYN at LMU College Hospital in Munich, Germany.
How Was the DESTINY-Breast11 Trial Designed?
Harbeck famous that present neoadjuvant standard-of-care (SOC) regimens for HER2-positive early breast most cancers have remained unchanged for greater than a decade. As such, investigators sought to guage Enhertu–primarily based remedy on this inhabitants with the objective of bettering efficacy and security versus the present SOC.
Sufferers have been randomly assigned to obtain Enhertu adopted by THP; ddAC-THP; or Enhertu alone, adopted by surgical procedure in all arms. Within the first arm, 321 sufferers obtained 4 cycles of Enhertu adopted by 4 cycles of THP. Within the second, ddAC was administered for 4 cycles, adopted by 4 cycles of THP. Within the ultimate arm, sufferers obtained Enhertu alone for eight cycles.
Notably, the Enhertu monotherapy arm was closed in March 2024, following a advice from the research’s unbiased knowledge monitoring committee.
After surgical procedure, research protocols referred to as for the next remedies, regardless of arm:
- pCR: radiotherapy and concomitant Herceptin with or with out Perjeta for as much as one yr
- Non-pCR: radiotherapy and Kadcyla for as much as 14 cycles
- Hormone receptor–optimistic illness: endocrine remedy
The research’s main finish level was pCR price. Secondary finish factors included event-free survival (EFS), security, pharmacokinetics, invasive disease-free survival, general survival and health-related high quality of life. Residual most cancers burden (RCB) was an extra consequence measured throughout the research.
At knowledge cutoff, 16.9% of sufferers within the Enhertu plus THP arm discontinued a research drug, together with Enhertu (2.8%) paclitaxel (14.4%) Herceptin (2.2%) and Perjeta (2.2%); 97.2% of sufferers on this arm proceeded to surgical procedure. Within the ddAC-THP arm, 13.8% of sufferers had discontinued any research remedy, together with AC (2.9%) paclitaxel (12%) Herceptin (3%) and Perjeta (3.7%); 93.8% of sufferers on this arm underwent surgical procedure. Within the Enhertu monotherapy arm (286 sufferers), 18.4% of sufferers discontinued research remedy and 95.8% underwent surgical procedure.
Relating to post-neoadjuvant remedies, 99.1% of evaluable sufferers within the Enhertu arm who achieved a pCR (226 sufferers) underwent any adjuvant remedy, comprising any cytotoxic chemotherapy routine (5.8%), any Kadcyla–containing routine (1.8%) and any Herceptin-containing routine (94.2%). Within the ddAC-THP, 98.4% of sufferers who achieved a pCR (190 sufferers) underwent any adjuvant remedy, together with any cytotoxic chemotherapy routine (5.8%), any Kadcyla–containing routine (2.1%) and any Herceptin-containing routine (91.6%).
For sufferers who didn’t obtain a pCR, any adjuvant remedy was administered to 89.5% of sufferers within the Enhertu plus THP arm (95 sufferers) and 82.3% of sufferers within the ddAC-THP arm (130 sufferers). Within the experimental group, adjuvant therapies included any cytotoxic chemotherapy routine (10.5%) any Kadcyla–containing routine (52.6%) and any Herceptin-containing routine (38.9%). These respective charges have been 9.2%, 56.9% and 26.2% within the management group.
Within the Enhertu plus THP and ddAC-THP arms, the median age was 50 years and 50 years, respectively. All sufferers in each arms have been feminine. The best proportion of sufferers in every arm was from Asia (Enhertu plus THP, 47.4%; ddAC-THP, 47.5%) and have been Asian (49.8%; 49.1%). Most sufferers had an ECOG efficiency standing of 0 (86.6%; 87.5%) had immunohistochemistry 3+ HER2-positive illness (87.2%; 88.4%) had cT0-2 tumors (54.8%; 58.8%) and had optimistic lymph nodes (89.4%; 87.8%).
What Have been the Different Efficacy Outcomes for Enhertu Plus THP Versus ddAC-THP?
Findings additionally confirmed that 81.3% of sufferers within the Enhertu plus THP arm had no RCB (RCB-0) or minimal RCB (RCB-1) in resected breast or lymph node tissue in contrast with 69.1% within the ddAC-THP arm (distinction, 12.2%). Within the hormone receptor–optimistic inhabitants, the RCB-0 plus RCB-1 charges have been 78% for Enhertu plus THP versus 64.7% for ddAC-THP; these respective charges have been 90.4% and 81.2% within the hormone receptor–damaging inhabitants.
Investigators additionally reported an EFS pattern favoring Enhertu plus THP, with knowledge at 4.5% maturity. Maturity for the information cutoff of the trial’s ultimate evaluation is predicted at roughly 10%. The 24-month EFS charges have been 96.9% within the Enhertu plus THP arm versus 93.1% within the ddAC-THP arm.
What Is the Aspect Impact Profile of Enhertu Plus THP?
Any-grade negative effects occurred in 98.1% of sufferers within the Enhertu plus THP arm in contrast with 98.7% of sufferers within the ddAC-THP arm. The respective charges of grade 3 (extreme) or increased negative effects have been 37.5% and 55.8%. Any-grade severe negative effects have been reported in 10.6% and 20.2% of sufferers, respectively.
Within the Enhertu plus THP arm, negative effects led to dose any dose discount, any drug interruption and any remedy discontinuation in 18.1%, 37.8% and 14.1% of sufferers, respectively. Within the ddAC-THP group, these charges have been 19.2%, 54.5% and 9.9%, respectively. Unwanted effects led to loss of life in 0.6% of sufferers in each arms. Unwanted effects led to delays in surgical procedure in 3.4% of sufferers within the experimental arm versus 2.6% of sufferers within the management arm.
Relating to negative effects of particular curiosity, any-grade drug-related adjudicated interstitial lung illness (ILD) was 4.4% within the Enhertu plus THP arm versus 5.1% within the ddAC-THP arm. The charges of grade 3 or increased ILD have been 0.6% and 1.9%, respectively. Grade 5 (deadly) ILD occurred in a single affected person (0.3%) in each teams. Any-grade left ventricular dysfunction occurred in 1.3% of sufferers within the experimental arm versus 6.1% of sufferers within the management arm. The charges of grade 3 or increased left ventricular dysfunction have been 0.3% and 1.9%, respectively, though no grade 5 occasions have been reported in both group.
Any-grade treatment-emergent negative effects reported in not less than 20% of sufferers in both arm included nausea (Enhertu plus THP, 64.7%; ddAC-THP, 51.6%) diarrhea (58.8%; 54.2%) alopecia (47.5%; 49.0%) fatigue (41.3%; 54.8%) elevated transaminase ranges (34.4%; 33.7%) neutropenia (29.1%; 44.2%) constipation (29.1%; 24.4%) vomiting (28.8%; 21.2%) peripheral neuropathy (25.9%; 20.8%) anemia (22.8%; 49.7%) stomatitis (18.4%; 27.9%) and leukopenia (17.2%; 23.4%).
What Information Have been Reported for Enhertu Monotherapy in HER2+ Early Breast Most cancers?
Within the Enhertu monotherapy arm, sufferers have been allowed to stay on remedy or instantly change to native SOC. If sufferers switched remedy, they have been categorised as having a non-pCR.
Findings from the monotherapy arm confirmed that 286 sufferers achieved a pCR price of 43% on the main evaluation and 51.4% at a prespecified supplementary evaluation. EFS knowledge have been related between Enhertu monotherapy and ddAC-THP, and the 24-month EFS price within the Enhertu monotherapy group was 94.4%.
Relating to security, 97.5% of sufferers handled with Enhertu alone (283 sufferers) skilled any-grade negative effects, 22.6% had grade 3 or increased negative effects, and 10.2% had any-grade severe negative effects. Unwanted effects led to dose discount, drug interruption and remedy discontinuation in 6.7%, 18% and seven.8% of sufferers, respectively. One affected person (0.4%) skilled a facet impact that led to loss of life. Unwanted effects led to surgical delay in 6.4% of sufferers.
The speed of any-grade drug-related adjudicated ILD was 4.9% within the Enhertu monotherapy arm, though all cases have been grade 1 (gentle) or 2 (reasonable). Left ventricular dysfunction occurred in 0.7% of sufferers, all at grade 1 or 2.
What’s Subsequent for Enhertu Plus THP?
Based mostly on knowledge from DESTINY-Breast11, the U.S. Meals and Drug Administration (FDA) accepted a supplemental biologics license software looking for the approval of neoadjuvant Enhertu adopted THP for the remedy of grownup sufferers with high-risk HER2-positive (IHC 3+ or in situ hybridization–optimistic) stage 2/3 breast most cancers.
The FDA has assigned a goal motion date of Might 18, 2026, underneath the Prescription Drug Person Price Act.
“DESTINY-Breast11 outcomes help [Enhertu plus] THP as a more practical and fewer poisonous neoadjuvant remedy in contrast with ddAC-THP, and it could turn out to be the popular routine for sufferers with high-risk HER2-positive early breast most cancers,” Harbeck concluded in her presentation.
References
- “DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or adopted by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast most cancers (eBC),” by Dr. Nadia Harbeck et al., offered at: 2025 ESMO Congress; October 17-21, 2025; Berlin, Germany. Summary 291O.
For extra information on most cancers updates, analysis and schooling,
